Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1611
This examiner grants 28% of resolved cases
Isis A. D. Ghali, in Tech Center 1600 and Art Unit 1611, has an allowance rate of 27.9% across 852 resolved cases. The median days to allowance is 1599, indicating a long prosecution process for those seeking a grant. This 1599-day figure and the 27.9% allowance rate reflect a challenging environment. Practitioners should prepare for a sustained effort when navigating applications under this examiner's review.
However, the interview lift is 41.6%, which is very high compared to the 27.9% allowance rate. This 41.6% lift suggests that interviews are a powerful tool for overcoming rejections. Given the 1599-day median pendency and the 852 resolved cases, early and frequent interviews are likely the most effective strategy. The 41.6% lift provides a significant opportunity to improve the probability of success beyond the 27.9% baseline in Art Unit 1611.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17503762 | MULTI-PHASE ORAL COMPOSITION FOR DELIVERING ORAL CARE ACTIVE AGENTS | Final Rejection | The Procter & Gamble Company |
| 18392417 | CHEWABLE GEL PRODUCTS FOR ACTIVE PHARMACEUTICAL INGREDIENTS | Non-Final OA | Bayer Healthcare LLC |
| 17840276 | METHODS TO ENHANCE BIOAVAVAILABILITY OF ORGANIC SMALL MOLECULES AND DEPOSITED FILMS MADE THEREFROM | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 18283379 | COSMETIC | Final Rejection | SHISEIDO COMPANY, LTD. |
| 18265324 | PERSONAL CARE COMPOSITION | Non-Final OA | Conopco, Inc., d/b/a UNILEVER |
| 18605521 | METHOD AND DEVICE FOR PROVIDING EFFECTIVE CONTRACEPTION | Final Rejection | Chemo Research, S.L. |
| 18295188 | COMPOSITION AND METHODS OF TREATMENT USING TRANSDERMAL SUPPLEMENTATION | Non-Final OA | Xygenyx Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy